Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Current Assets (2016 - 2026)

Cytosorbents filings provide 16 years of Current Assets readings, the most recent being $20.6 million for Q4 2025.

  • On a quarterly basis, Current Assets fell 4.49% to $20.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $20.6 million, a 4.49% decrease, with the full-year FY2025 number at $20.6 million, down 4.49% from a year prior.
  • Current Assets hit $20.6 million in Q4 2025 for Cytosorbents, down from $21.3 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $79.6 million in Q1 2021 to a low of $16.6 million in Q3 2024.
  • Median Current Assets over the past 5 years was $25.4 million (2023), compared with a mean of $36.2 million.
  • Biggest five-year swings in Current Assets: surged 112.19% in 2021 and later tumbled 55.49% in 2022.
  • Cytosorbents' Current Assets stood at $64.3 million in 2021, then tumbled by 47.5% to $33.8 million in 2022, then fell by 24.77% to $25.4 million in 2023, then fell by 14.94% to $21.6 million in 2024, then dropped by 4.49% to $20.6 million in 2025.
  • The last three reported values for Current Assets were $20.6 million (Q4 2025), $21.3 million (Q3 2025), and $23.0 million (Q2 2025) per Business Quant data.